HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Abrogation of β-catenin signaling in oligodendrocyte precursor cells reduces glial scarring and promotes axon regeneration after CNS injury.

Abstract
When the brain or spinal cord is injured, glial cells in the damaged area undergo complex morphological and physiological changes resulting in the formation of the glial scar. This scar contains reactive astrocytes, activated microglia, macrophages and other myeloid cells, meningeal cells, proliferating oligodendrocyte precursor cells (OPCs), and a dense extracellular matrix. Whether the scar is beneficial or detrimental to recovery remains controversial. In the acute phase of recovery, scar-forming astrocytes limit the invasion of leukocytes and macrophages, but in the subacute and chronic phases of injury the glial scar is a physical and biochemical barrier to axonal regrowth. The signals that initiate the formation of the glial scar are unknown. Both canonical and noncanonical signaling Wnts are increased after spinal cord injury (SCI). Because Wnts are important regulators of OPC and oligodendrocyte development, we examined the role of canonical Wnt signaling in the glial reactions to CNS injury. In adult female mice carrying an OPC-specific conditionally deleted β-catenin gene, there is reduced proliferation of OPCs after SCI, reduced accumulation of activated microglia/macrophages, and reduced astrocyte hypertrophy. Using an infraorbital optic nerve crush injury, we show that reducing β-catenin-dependent signaling in OPCs creates an environment that is permissive to axonal regeneration. Viral-induced expression of Wnt3a in the normal adult mouse spinal cord induces an injury-like response in glia. Thus canonical Wnt signaling is both necessary and sufficient to induce injury responses among glial cells. These data suggest that targeting Wnt expression after SCI may have therapeutic potential in promoting axon regeneration.
AuthorsJustin P Rodriguez, Michael Coulter, Jill Miotke, Ronald L Meyer, Ken-Ichi Takemaru, Joel M Levine
JournalThe Journal of neuroscience : the official journal of the Society for Neuroscience (J Neurosci) Vol. 34 Issue 31 Pg. 10285-97 (Jul 30 2014) ISSN: 1529-2401 [Electronic] United States
PMID25080590 (Publication Type: Journal Article)
CopyrightCopyright © 2014 the authors 0270-6474/14/3410285-13$15.00/0.
Chemical References
  • Glial Fibrillary Acidic Protein
  • Luminescent Proteins
  • Selective Estrogen Receptor Modulators
  • beta Catenin
  • Tamoxifen
  • Receptor, Platelet-Derived Growth Factor alpha
  • Bromodeoxyuridine
Topics
  • Animals
  • Bromodeoxyuridine (metabolism)
  • Central Nervous System Diseases (physiopathology, therapy)
  • Cicatrix (etiology, pathology)
  • Disease Models, Animal
  • Gene Transfer Techniques
  • Glial Fibrillary Acidic Protein (metabolism)
  • In Vitro Techniques
  • Luminescent Proteins (genetics)
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Nerve Regeneration (physiology)
  • Oligodendroglia (metabolism)
  • Optic Nerve Diseases (pathology, physiopathology)
  • Receptor, Platelet-Derived Growth Factor alpha (genetics)
  • Selective Estrogen Receptor Modulators (pharmacology)
  • Signal Transduction (genetics)
  • Tamoxifen (pharmacology)
  • beta Catenin (deficiency)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: